drugset
drugset / Trial / NCT05439148

OPC-61815 in Healthy Chinese Male Subjects

NCT05439148 ↗

Phase 1 Completed 18 enrolled Otsuka Beijing Research Institute
NaSequentialOpen-labelTreatment

Summary

To evaluate the pharmacokinetic (PK) characteristics and pharmacological effect of OPC-61815 in healthy Chinese Male subjects

Timeline

Start
2022-06-30
Primary completion
2022-09-21
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject OPC-61815 Unknown 8 mg Intravenous
Subject OPC-61815 Unknown 16 mg Intravenous

Indications

No indication recorded.